Showing results (31-40 of 78) with videos related to
Sort By:
Pageof 8
Journal of Market Access & Health Policy|May 10, 2021
Trends in US emergency department visits and subsequent hospital admission among patients with inflammatory bowel disease presenting with abdominal pain: a real-world study from a national emergency department sample databaseZhijie Ding, Aarti Patel, James Izanec, et al.IEEE Journal of Biomedical and Health Informatics|December 18, 2020
An Optimal Channel Selection for EEG-Based Depression Detection via Kernel-Target AlignmentJian Shen, Xiaowei Zhang, Xiao Huang, et al.Oncology Reports|November 27, 2010
Differential methylation of CpG islands within the dermo1 gene promoter in several cancer cell linesYubin Mao, Hween-Boon Toh, Zhijie Ding, et al.Frontiers in Neuroscience|April 10, 2023
Ensemble learning with speaker embeddings in multiple speech task stimuli for depression detectionZhenyu Liu, Huimin Yu, Gang Li, et al.Patient Preference and Adherence|April 15, 2024
Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative ColitisMaryia Zhdanava, Sumesh Kachroo, Aditi Shah, et al.Clinical Therapeutics|July 13, 2023
Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic AgentMaryia Zhdanava, Sumesh Kachroo, Ameur M Manceur, et al.Crohn'S & Colitis 360|February 13, 2023
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional AgentsDominic Pilon, Zhijie Ding, Erik Muser, et al.Journal of Managed Care & Specialty Pharmacy|July 31, 2023
Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumabMaryia Zhdanava, Ruizhi Zhao, Ameur M Manceur, et al.Current Medical Research and Opinion|August 11, 2023
Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumabMaryia Zhdanava, Zhijie Ding, Ameur M Manceur, et al.Blood Advances|May 12, 2025
Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLLJohn N Allan, Tao Ran, Zhijie Ding, et al.Pageof 8